Tempest Therapeutics suspends ATM prospectus; Sales Agreement remains in effect

Tempest Therapeutics, Inc.

Delivered notice to Jefferies to terminate ATM prospectus dated Feb 6, 2025.
No sales of common stock under Sales Agreement until new prospectus filed.
Underlying Open Market Sale Agreement with Jefferies remains in full force.
Company retains ability to resume ATM sales after filing new prospectus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.